Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy-Reference-Cited by-同舟云学术

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Published:2021-05 Issue:5 Volume:32 Page:642-651
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Du L.,Yau C.,Brown-Swigart L.,Gould R.,Krings G.,Hirst G.L.,Bedrosian I.,Layman R.M.,Carter J.M.,Klein M.,Venters S.,Shad S.,van der Noordaa M.,Chien A.J.,Haddad T.,Isaacs C.,Pusztai L.,Albain K.,Nanda R.,Tripathy D.,Liu M.C.,Boughey J.,Schwab R.,Hylton N.,DeMichele A.,Perlmutter J.,Yee D.,Berry D.,van't Veer L.,Valero V.,Esserman L.J.,Symmans W.F.^ORCID

Funder

National Cancer Institute

Cancer Prevention and Research Institute of Texas

Breast Cancer Research Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer;Sparano;J Clin Oncol,2015

2. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance);Liu;NPJ Breast Cancer,2016

3. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017